Literature DB >> 1436347

Retroviral envelope glycoprotein (gp 70) is not a prerequisite for pathogenesis of primary immunoglobulin A nephropathy in ddY mice.

M Shimizu1, Y Tomino, M Abe, T Shirai, H Koide.   

Abstract

Deposition of a major retroviral envelope glycoprotein, gp 70, in renal glomeruli of ddY mice, an animal model for primary IgA nephropathy, was examined by immunofluorescence. The positive staining of gp 70 was not observed in glomeruli of our substrain of ddY mice at any ages examined using two different anti-gp 70 antisera and three different staining conditions, whereas deposition of IgA, IgG and IgM was manifest in mice aged over 40 weeks. As a control, NZB x NZW F1 mice from 4 months of age onwards showed severe glomerular deposition of gp 70, in keeping with previous reports. Thus, it appears that gp 70 deposition may not be sine qua non for the pathogenesis of IgA nephropathy of all substrains of ddY mice.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1436347     DOI: 10.1159/000187068

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  3 in total

Review 1.  Pathogenetic and therapeutic approaches to IgA nephropathy using a spontaneous animal model, the ddY mouse.

Authors:  Yasuhiko Tomino
Journal:  Clin Exp Nephrol       Date:  2010-11-06       Impact factor: 2.801

2.  Development of a model of early-onset IgA nephropathy.

Authors:  Keiko Okazaki; Yusuke Suzuki; Mareki Otsuji; Hitoshi Suzuki; Masao Kihara; Tadahiro Kajiyama; Azusa Hashimoto; Hiroyuki Nishimura; Rhubell Brown; Stacy Hall; Jan Novak; Shozo Izui; Sachiko Hirose; Yasuhiko Tomino
Journal:  J Am Soc Nephrol       Date:  2012-07-12       Impact factor: 10.121

3.  Uncoupling of glomerular IgA deposition and disease progression in alymphoplasia mice with IgA nephropathy.

Authors:  Masashi Aizawa; Yusuke Suzuki; Hitoshi Suzuki; Huihua Pang; Masao Kihara; Junichiro Nakata; Kenji Yamaji; Satoshi Horikoshi; Yasuhiko Tomino
Journal:  PLoS One       Date:  2014-04-17       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.